| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/08/2000 | CA2303752A1 Renal cell carcinoma treatment |
| 10/08/2000 | CA2266760A1 Methylation of arginine and related amino acids |
| 10/05/2000 | WO2000058523A1 Glucocorticoid receptor agonist and decreased pp5 |
| 10/05/2000 | WO2000058513A1 49 human secreted proteins |
| 10/05/2000 | WO2000058512A1 Antisense modulation of interleukin-5 signal transduction |
| 10/05/2000 | WO2000058511A1 Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
| 10/05/2000 | WO2000058506A2 Susceptibility to psoriasis |
| 10/05/2000 | WO2000058496A1 50 human secreted proteins |
| 10/05/2000 | WO2000058495A1 45 human secreted proteins |
| 10/05/2000 | WO2000058494A1 50 human secreted proteins |
| 10/05/2000 | WO2000058483A2 Protozoan expression system |
| 10/05/2000 | WO2000058475A2 Streptococcus pneumoniae antigens |
| 10/05/2000 | WO2000058473A2 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 10/05/2000 | WO2000058470A1 Prostate-specific gene, pcgem1, and methods of using pcgem1 to detect, treat, and prevent prostate cancer |
| 10/05/2000 | WO2000058469A1 48 human secreted proteins |
| 10/05/2000 | WO2000058468A2 47 human secreted proteins |
| 10/05/2000 | WO2000058467A1 50 human secreted proteins |
| 10/05/2000 | WO2000058466A2 Protease resistant flint analogs |
| 10/05/2000 | WO2000058465A2 Flint polypeptide analogs |
| 10/05/2000 | WO2000058463A1 Polynucleotide and deduced amino acid sequences from stromal cells |
| 10/05/2000 | WO2000058460A2 Casb619 involved in colon cancers |
| 10/05/2000 | WO2000058456A2 Compositions and methods for modifying toxic effects of proteinacious compounds |
| 10/05/2000 | WO2000058441A1 STAPHYLOCOCCUS AUREUS ydjB RELATED TO THE LUXS AUTOINDUCER SYNTHESIS FAMILY |
| 10/05/2000 | WO2000058365A1 Specific binding proteins for treating canine allergy |
| 10/05/2000 | WO2000058363A1 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 10/05/2000 | WO2000058362A1 Neutrokine-alpha binding proteins and methods based thereon |
| 10/05/2000 | WO2000058361A1 Melanocortin receptor ligands |
| 10/05/2000 | WO2000058360A2 Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
| 10/05/2000 | WO2000058359A1 Retro-inverso prosaposin-derived peptides and use thereof |
| 10/05/2000 | WO2000058358A1 49 human secreted proteins |
| 10/05/2000 | WO2000058357A1 50 human secreted proteins |
| 10/05/2000 | WO2000058356A1 50 human secreted proteins |
| 10/05/2000 | WO2000058355A1 50 human secreted proteins |
| 10/05/2000 | WO2000058354A1 Peptides useful in treating multiple sclerosis and a pharmaceutical composition comprising the same |
| 10/05/2000 | WO2000058353A1 Npcahh01: human transmembrane protein e3-16 gene |
| 10/05/2000 | WO2000058350A1 49 human secreted proteins |
| 10/05/2000 | WO2000058349A1 Peptide vaccine for canine allergy |
| 10/05/2000 | WO2000058348A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| 10/05/2000 | WO2000058347A1 Cosmetic or dermopharmaceutical compositions containing tripeptide n-biotinyl-gly-his-lys for the prevention, reduction or suppression of hair loss and stimulation of regrowth |
| 10/05/2000 | WO2000058346A1 N-sulfonyl-dipeptide derivatives, production and use thereof in therapy |
| 10/05/2000 | WO2000058341A1 Hookworm platelet inhibitor |
| 10/05/2000 | WO2000058340A2 50 human secreted proteins |
| 10/05/2000 | WO2000058339A2 50 human secreted proteins |
| 10/05/2000 | WO2000058336A1 50 human secreted proteins |
| 10/05/2000 | WO2000058335A1 47 human secreted proteins |
| 10/05/2000 | WO2000058334A1 50 human secreted proteins |
| 10/05/2000 | WO2000058332A1 Antisense modulation of sra expression |
| 10/05/2000 | WO2000058331A1 Mvd |
| 10/05/2000 | WO2000058271A1 Nitrogen mustard compounds and prodrugs therefor |
| 10/05/2000 | WO2000057922A1 Intramyocardial injection of autologous bone marrow |
| 10/05/2000 | WO2000057921A2 Peroral gene therapy of diabetes and obesity |
| 10/05/2000 | WO2000057920A2 Method for expressing proteins |
| 10/05/2000 | WO2000057905A1 Recombinant neospora antigens and their uses |
| 10/05/2000 | WO2000057903A2 48 human secreted proteins |
| 10/05/2000 | WO2000057902A1 Method and pharmaceutical composition for wound healing |
| 10/05/2000 | WO2000057901A1 Modulation of vascular permeability by means of tie2 receptor activators |
| 10/05/2000 | WO2000057900A2 Factor for regulation of neurite growth |
| 10/05/2000 | WO2000057899A1 Thrombospondin-2 and uses thereof |
| 10/05/2000 | WO2000057898A1 Compositions for reducing blood cholesterol |
| 10/05/2000 | WO2000057897A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 10/05/2000 | WO2000057896A1 Modulators of polysaccharides and uses thereof |
| 10/05/2000 | WO2000057895A1 Method for pr-39 peptide regulated stimulation of angiogenesis |
| 10/05/2000 | WO2000057892A1 Use of a serenoa repens extract for the production of a medicament to treat prostate cancer |
| 10/05/2000 | WO2000057891A1 Compositions and methods for producing platelets and/or proplatelets from megakaryocytes |
| 10/05/2000 | WO2000057879A1 Treatment of brain changes with myelin protective agents |
| 10/05/2000 | WO2000057878A1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment |
| 10/05/2000 | WO2000057870A2 Viral treatment |
| 10/05/2000 | WO2000057866A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 10/05/2000 | WO2000057861A2 Use of cytidine derivatives for the treatment of leukaemia |
| 10/05/2000 | WO2000057837A2 Compositions and methods for effecting the levels of cholesterol |
| 10/05/2000 | WO2000057719A1 Additives for crustacean or fish feeds and feeds |
| 10/05/2000 | WO2000031133A3 Potassium channel interactors and uses therefor |
| 10/05/2000 | WO2000030588A3 Treatment of hypertension |
| 10/05/2000 | WO2000029574A3 Inflammation-associated genes |
| 10/05/2000 | WO2000029433A3 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines |
| 10/05/2000 | WO2000028039A3 Identification of senv genotypes |
| 10/05/2000 | WO2000027880A3 Rantes-derived peptides with anti-hiv activity |
| 10/05/2000 | WO2000027421A3 LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE |
| 10/05/2000 | WO2000026379A3 Polypeptide mediating cell permeability |
| 10/05/2000 | WO2000026246A3 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 10/05/2000 | WO2000026243A3 Transmembrane 4 proteins |
| 10/05/2000 | WO2000025811A3 Multicomponent meningococcal vaccine |
| 10/05/2000 | WO2000025804A3 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 10/05/2000 | WO2000020638A9 Methods and compositions for the diagnosis and therapy of prostate cancer |
| 10/05/2000 | WO2000020625A9 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 10/05/2000 | WO2000016765A9 Method and composition for treatment of inflammatory bowel disease |
| 10/05/2000 | WO2000014248A8 Cyclic nucleotide-associated proteins |
| 10/05/2000 | WO2000013701A9 Angiogenically effective unit dose of fgf-2 and method of use |
| 10/05/2000 | WO2000011167A3 Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof |
| 10/05/2000 | WO2000005249A3 Synthetic peptides and methods of use for autoimmune disease therapies |
| 10/05/2000 | WO1999032135A8 Keratinocyte growth factor-2 formulations |
| 10/05/2000 | WO1998041232A3 Compositions for modulating responsiveness to corticosteroids |
| 10/05/2000 | DE19914817A1 New DNA for the multiple peptide resistance factor of Staphylococcus, useful for identifying agents that increase bacterial sensitivity to antimicrobial peptides |
| 10/05/2000 | DE19914345A1 Improving appearance of teeth and gums, e.g., after parodontosis treatment, by gradual injection of collagen into papillae so that damage to gum tissue is minimized |
| 10/05/2000 | CA2383592A1 2384891 acids including open reading frames encoding polypeptides; orfx |
| 10/05/2000 | CA2370441A1 50 human secreted proteins |
| 10/05/2000 | CA2369458A1 47 human secreted proteins |
| 10/05/2000 | CA2369009A1 Factor for regulation of neurite growth |
| 10/05/2000 | CA2368951A1 50 human secreted proteins |
| 10/05/2000 | CA2368927A1 45 human secreted proteins |